Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Cardiovascular effects of RTR2996, a single stranded oligonucleotide, in the minipig.

Roberts S, Greiter-Wilke A, Waiz D, Jenni R, Weile C, Zihlmann M, Tessier Y, Braendli-Baiocco A, Festag M.

J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.146. Epub 2019 Oct 17. No abstract available.

PMID:
31962955
2.

Pediatric Safety of Polysorbates in Drug Formulations.

Kriegel C, Festag M, Kishore RSK, Roethlisberger D, Schmitt G.

Children (Basel). 2019 Dec 20;7(1). pii: E1. doi: 10.3390/children7010001.

3.

Interspecies Variation of Outer Retina and Choriocapillaris Imaged With Optical Coherence Tomography.

Soukup P, Maloca P, Altmann B, Festag M, Atzpodien EA, Pot S.

Invest Ophthalmol Vis Sci. 2019 Aug 1;60(10):3332-3342. doi: 10.1167/iovs.18-26257.

PMID:
31370061
4.

Assessment of Preclinical Liver and Skeletal Muscle Biomarkers Following Clofibrate Administration in Wistar Rats.

Maliver P, Festag M, Bennecke M, Christen F, Bánfai B, Lenz B, Winter M.

Toxicol Pathol. 2017 Jun;45(4):506-525. doi: 10.1177/0192623317707271. Epub 2017 May 9.

PMID:
28485676
5.

Inhibition of EGF Uptake by Nephrotoxic Antisense Drugs In Vitro and Implications for Preclinical Safety Profiling.

Moisan A, Gubler M, Zhang JD, Tessier Y, Dumong Erichsen K, Sewing S, Gérard R, Avignon B, Huber S, Benmansour F, Chen X, Villaseñor R, Braendli-Baiocco A, Festag M, Maunz A, Singer T, Schuler F, Roth AB.

Mol Ther Nucleic Acids. 2017 Mar 17;6:89-105. doi: 10.1016/j.omtn.2016.11.006. Epub 2016 Dec 10.

6.

From the Cover: The Minipig is a Suitable Non-Rodent Model in the Safety Assessment of Single Stranded Oligonucleotides.

Braendli-Baiocco A, Festag M, Dumong Erichsen K, Persson R, Mihatsch MJ, Fisker N, Funk J, Mohr S, Constien R, Ploix C, Brady K, Berrera M, Altmann B, Lenz B, Albassam M, Schmitt G, Weiser T, Schuler F, Singer T, Tessier Y.

Toxicol Sci. 2017 May 1;157(1):112-128. doi: 10.1093/toxsci/kfx025.

7.

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G.

Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14.

8.

Vehicle Systems and Excipients Used in Minipig Drug Development Studies.

Weaver ML, Grossi AB, Schützsack J, Parish J, Løgsted J, Bøgh IB, Cameron D, Harvey W, Festag M, Downes N, Venturella S, Schlichtiger J, Mhedhbi S, Ross V, Kissner T, Stark C, Milano S, Heining P, Sanchez-Felix M.

Toxicol Pathol. 2016 Apr;44(3):367-72. doi: 10.1177/0192623315613088. Epub 2015 Dec 16. Review.

PMID:
26674803
9.

Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.

Sewell F, Chapman K, Baldrick P, Brewster D, Broadmeadow A, Brown P, Burns-Naas LA, Clarke J, Constan A, Couch J, Czupalla O, Danks A, DeGeorge J, de Haan L, Hettinger K, Hill M, Festag M, Jacobs A, Jacobson-Kram D, Kopytek S, Lorenz H, Moesgaard SG, Moore E, Pasanen M, Perry R, Ragan I, Robinson S, Schmitt PM, Short B, Lima BS, Smith D, Sparrow S, van Bekkum Y, Jones D.

Regul Toxicol Pharmacol. 2014 Oct;70(1):413-29. doi: 10.1016/j.yrtph.2014.07.018. Epub 2014 Jul 29.

10.

Genotoxicity testing of peptides: folate deprivation as a marker of exaggerated pharmacology.

Guérard M, Zeller A, Festag M, Schubert C, Singer T, Müller L.

Toxicol Appl Pharmacol. 2014 Sep 15;279(3):419-427. doi: 10.1016/j.taap.2014.06.022. Epub 2014 Jul 2.

PMID:
24997324
11.

Assessment of the genotoxic potential of azidothymidine in the comet, micronucleus, and Pig-a assay.

Guérard M, Koenig J, Festag M, Dertinger SD, Singer T, Schmitt G, Zeller A.

Toxicol Sci. 2013 Oct;135(2):309-16. doi: 10.1093/toxsci/kft148. Epub 2013 Jun 28.

PMID:
23811826
12.

A global pharmaceutical company initiative: an evidence-based approach to define the upper limit of body weight loss in short term toxicity studies.

Chapman K, Sewell F, Allais L, Delongeas JL, Donald E, Festag M, Kervyn S, Ockert D, Nogues V, Palmer H, Popovic M, Roosen W, Schoenmakers A, Somers K, Stark C, Stei P, Robinson S.

Regul Toxicol Pharmacol. 2013 Oct;67(1):27-38. doi: 10.1016/j.yrtph.2013.04.003. Epub 2013 Apr 19.

13.

Morphologic and functional effects of gamma secretase inhibition on splenic marginal zone B cells.

de Vera Mudry MC, Regenass-Lechner F, Ozmen L, Altmann B, Festag M, Singer T, Müller L, Jacobsen H, Flohr A.

Int J Alzheimers Dis. 2012;2012:289412. doi: 10.1155/2012/289412. Epub 2012 Dec 17.

14.

A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.

Robinson S, Delongeas JL, Donald E, Dreher D, Festag M, Kervyn S, Lampo A, Nahas K, Nogues V, Ockert D, Quinn K, Old S, Pickersgill N, Somers K, Stark C, Stei P, Waterson L, Chapman K.

Regul Toxicol Pharmacol. 2008 Apr;50(3):345-52. doi: 10.1016/j.yrtph.2007.11.009. Epub 2007 Dec 5.

PMID:
18295384
15.
16.

An in vitro embryotoxicity assay based on the disturbance of the differentiation of murine embryonic stem cells into endothelial cells. II. Testing of compounds.

Festag M, Viertel B, Steinberg P, Sehner C.

Toxicol In Vitro. 2007 Dec;21(8):1631-40. Epub 2007 Jul 18.

PMID:
17719739

Supplemental Content

Loading ...
Support Center